Shares of Schering-Plough have fallen 20 percent since the drugmaker said Vytorin failed to meet its primary goal of helping to prevent fatty plaque build-up in carotid arteries than generic cholesterol fighter simvastatin.

«« Defibrillators can be Interfered With from Outside Sources


US Healthcare Spending to Soar, Say Government Officials »»


Latest Articles

Shares of Schering-Plough have fallen 20 percent since the drugmaker said Vytorin failed to meet its primary goal of helping to prevent fatty plaque buil...